Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

ACCL vs TLPH: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ACCL Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 6–4 Matrix Metrics)

ACCL Overall Winner 6-Pillar Tally: ACCL 3 – 2 TLPH (1 Tie) Matrix Metrics: ACCL 6 – 4 TLPH

As of Nov 16, 2026, ACCL (ACCL) is the stronger overall head-to-head candidate over Talphera, Inc. (TLPH) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, R&D & Supply-Chain Moat). ACCL carries a Unified Composite Score of 63.4/100 (BUY) at $2.36 (N/M Forward P/E, 4.5% operating margin), whereas TLPH carries 37.1/100 (SELL) at $0.86 (1.0x Forward P/E, -1474700.0% operating margin).

  • Technical & Structure Timing Caution: ACCL is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 39.2); meanwhile TLPH is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 26.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ACCL vs TLPH
ACCL US Equity Head-to-Head Winner
ACCL
Institutional Equity
$2.36
-0.84% 1D
Market Cap $33.5M
TTM Revenue $5.2M
Forward P/E N/M
Beta / 30D Vol -0.20β · 60% Vol
Unified Composite Score
63.4 / 100 BUY
Tech 68.0 Fund 58.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -4.9%), weak momentum, RSI 39
RSI-14: 39.2 · SMA20: $2.54 · SMA50: $2.65
TLPH NASDAQ
Talphera, Inc. Common Stock
Pharmaceutical Preparations
$0.86
-4.98% 1D
Market Cap $53.7M
TTM Revenue $1,000
Forward P/E 1.0x
Beta / 30D Vol 1.11β · 58% Vol
Unified Composite Score
37.1 / 100 SELL
Tech 25.0 Fund 45.0 Flow 50.0 Mom 59.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -6.8%), weak momentum, RSI 26
RSI-14: 26.1 · SMA20: $1.04 · SMA50: $1.10

6-Pillar Scorecard Institutional Category Breakdown (ACCL 3 – 2 TLPH)

Columns: Metric · ACCL · TLPH
1. Valuation Multiples TLPH
Forward P/E N/M 1.0x
Trailing P/E 120.0x 1.0x
PEG Ratio N/M N/M
EV / Revenue 6.5x N/M
2. Growth & Scale TLPH
Revenue Growth (YoY) +11.3% +0.0%
Earnings Growth (YoY) -62.5% +0.0%
TTM Revenue (USD) $5.2M $1,000
Market Cap $33.5M $53.7M
3. Profitability & Quality ACCL
Gross Margin 42.4% N/A
Operating Margin 4.5% -1474700.0%
Net Profit Margin 5.5% 0.0%
Return on Equity (ROE) 7.0% -143.4%
4. Balance Sheet & Cash Flow ACCL
Cash Generation (TTM) $245,425 EBITDA -$15M EBITDA
Cash Flow Margin 4.7% EBITDA Mgn N/A
Net Cash / Leverage $0.43 Book/Sh · 7.0% ROE $0.28 Book/Sh · -143.4% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) 118.4% (100th %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat ACCL
OpEx & R&D Intensity 37.9% of Rev ($2.0M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Consulting Services Operator Drug Manufacturers - Specialty & Generic Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ACCL (6) vs TLPH (4)
Institutional Metric ACCL TLPH Criterion Row Edge
Market Capitalization
Scale
$33.5M $53.7M Larger Scale TLPH
Trailing P/E Ratio
Valuation
120.0x 1.0x Lower Multiple TLPH
Forward P/E Ratio
Valuation
N/M 1.0x Lower Multiple TLPH
Revenue Growth (YoY)
Growth
+11.3% +0.0% Higher Growth ACCL
Operating Margin (TTM)
Profitability
4.5% -1474700.0% Higher Margin ACCL
Net Profit Margin
Profitability
5.5% 0.0% Higher Margin ACCL
Return on Equity (ROE)
Capital Efficiency
7.0% -143.4% Higher ROE ACCL
52-Week Range Position
Momentum
30% ($1–$5) 20% ($1–$2) Stronger Trend ACCL
Beta / 30D Volatility
Risk Regime
-0.20β · 60% Vol 1.11β · 58% Vol Lower Realized Risk TLPH
Unified Institutional Score
Composite Signal
63.4 / 100 (BUY) 37.1 / 100 (SELL) Higher Composite ACCL
Trailing 12M Revenue (USD)
Operating Scale
$5.2M $1,000 FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
42.4% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 6.5x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$245,425 EBITDA ($0.43 Book/Sh · 7.0% ROE) -$15M EBITDA ($0.28 Book/Sh · -143.4% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ACCL +6.52 pp
ACCL: -12.26% · TLPH: -18.78%
3M Horizon ACCL +13.11 pp
ACCL: -16.9% · TLPH: -30.01%
6M Horizon ACCL +64.63 pp
ACCL: +60.55% · TLPH: -4.08%
1Y Horizon TLPH +25.66 pp
ACCL: -43.67% · TLPH: -18.01%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ACCL vs TLPH. Trailing 12-month operating profitability (ACCL 4.5% vs TLPH -1474700.0%) and valuation multiples (ACCL N/M vs TLPH 1.0x Forward P/E) are benchmarked directly in Pillar 4 below.

ACCL ADR TTM Benchmark FX-Normalized USD
TTM Revenue$5.2M
Gross Margin42.4%
Op. Margin4.5%
ROE / Fwd P/E7.0% · N/M
TLPH ADR TTM Benchmark FX-Normalized USD
TTM Revenue$1,000
Gross MarginN/A
Op. Margin-1474700.0%
ROE / Fwd P/E-143.4% · 1.0x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ACCL UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact ACCL Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
TLPH UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 118.4%
IV Percentile 100th %ile
Put/Call OI Skew N/A
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact TLPH Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ACCL Moat Profile Cyclical / Execution-Driven Positioning
Consulting Services Operator
Competes within the Consulting Services value chain with $33.5M market capitalization and 4.5% operating margin.
OpEx & R&D Reinvestment 37.9% of Rev ($2.0M)
90D Engineering Disclosures 0 Published
TLPH Moat Profile Cyclical / Execution-Driven Positioning
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $53.7M market capitalization and -1474700.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ ACCL vs TLPH Key Questions & Quantitative Answers

As of Nov 16, 2026, ACCL (ACCL) is the stronger overall head-to-head candidate over Talphera, Inc. (TLPH) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, R&D & Supply-Chain Moat). ACCL carries a Unified Composite Score of 63.4/100 (BUY) at $2.36 (N/M Forward P/E, 4.5% operating margin), whereas TLPH carries 37.1/100 (SELL) at $0.86 (1.0x Forward P/E, -1474700.0% operating margin). Technical & Structure Timing Caution: ACCL is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 39.2); meanwhile TLPH is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 26.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

TLPH leads the Growth & Scale pillar: ACCL posts +11.3% YoY revenue growth and -62.5% YoY earnings growth on $5.2M TTM revenue (42.4% gross margin, 4.5% operating margin), compared with TLPH at +0.0% YoY revenue growth and +0.0% YoY earnings growth on $1,000 TTM revenue (N/A gross margin, -1474700.0% operating margin). On trailing 12-month operating scale, ACCL generates $5.2M in USD-normalized revenue versus $1,000 for TLPH. In operating R&D and SG&A reinvestment, ACCL deploys 37.9% of Rev ($2.0M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for TLPH.

TLPH screens cheaper on headline valuation multiples. ACCL trades at N/M Forward P/E, 120.0x Trailing P/E, N/M PEG, and 6.5x EV/Revenue (4.7% EBITDA margin), whereas TLPH trades at 1.0x Forward P/E, 1.0x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ACCL (7.0% ROE) versus TLPH (-143.4% ROE) capital efficiency.

In options market volatility and institutional positioning, ACCL carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-0.20β · 60% Vol realized risk). By comparison, TLPH carries 118.4% implied volatility (100th %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.11β · 58% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.